Company Profile

Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.

Employees

Sector

Biotechnology & Medical Research

More about the company

16/12/19	Fibrocell Science, Inc.(NasdaqGM:FCSC) dropped from S&P TMI Index	CI
13/12/19	Fibrocell Science, Inc.(NasdaqGM:FCSC) dropped from NASDAQ Composite Index	CI

16/12/19	Fibrocell Science, Inc.(NasdaqGM:FCSC) dropped from S&P TMI Index	CI
13/12/19	Fibrocell Science, Inc.(NasdaqGM:FCSC) dropped from NASDAQ Composite Index	CI
13/12/19	Castle Creek Pharmaceutical Holdings, Inc. completed the acquisition of Fibrocell Science, Inc..	CI
15/11/19	Fibrocell Science, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	CI
12/09/19	Castle Creek Pharmaceutical Holdings, Inc. entered into a definitive agreement to acquire Fibrocell Science, Inc. for $63.3 million.	CI
23/08/19	Fibrocell Science, Inc Appoints Sean D. Buckley as Chief Financial Officer	CI
15/08/19	Fibrocell Science, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	CI
29/05/19	Fibrocell Science, Inc. Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB	CI
16/05/19	Fibrocell Science, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	CI
15/04/19	Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy	CI
28/03/19	Fibrocell Science, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	CI
27/03/19	Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007	CI
27/03/19	Fibrocell Science, Inc. Auditor Raises 'Going Concern' Doubt	CI

18/12/19	Fibrocell Science : Castle Creek Pharmaceutical Holdings Completes Acquisition of Fibrocell Science	AQ
14/12/19	FIBROCELL SCIENCE, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
11/12/19	FIBROCELL SCIENCE, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
22/11/19	FIBROCELL SCIENCE, INC. : Other Events (form 8-K)	AQ
18/09/19	FIBROCELL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fibrocell Science, Inc. - FCSC	BU

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+1.15%	+9.07%	-3.67%	+4.36%	46.62B
REVOLUTION MEDICINES, INC.	-1.79%	+9.56%	+404.78%	+594.24%	40.95B
IQVIA HOLDINGS INC.	-3.23%	+12.97%	+22.79%	-13.91%	32.26B
BEONE MEDICINES AG	+0.13%	+3.24%	+17.77%	+59.89%	32.24B
CELLTRION, INC.	-3.29%	+2.85%	+13.80%	+30.30%	25.53B
ASCENDIS PHARMA A/S	+32.41%	+11.91%	-	-	16.38B
MEDPACE HOLDINGS, INC.	-5.03%	+11.95%	+68.88%	+120.70%	15.27B
EUROFINS SCIENTIFIC SE	+0.56%	+8.00%	+12.65%	+21.35%	13.61B
IONIS PHARMACEUTICALS, INC.	-3.50%	+4.82%	+101.59%	+94.13%	13.34B
Average	-0.63%	+10.33%	+79.82%	+113.88%	26.24B
Weighted average by Cap.	-0.63%	+10.36%	+93.92%	+137.31%

Fibrocell Science Inc Stock NYSE

Stocks

US3157212099

Biotechnology & Medical Research

Latest news : Fibrocell Science Inc

Press Releases: Fibrocell Science Inc

Other Biotechnology & Medical Research

Company Profile

End-of-day quote NYSE Other stock markets
- ^USD	-